#USA #Portland #Axogen #Trace Biosciences #Nerve Imaging

Trace Biosciences Secures Major Investment for Nerve Imaging Technology

Trace Biosciences, Inc., a biotechnology firm that specializes in clinical-stage development of nerve-targeted imaging agents, has successfully secured a strategic investment from Axogen, Inc. This investment, part of Trace Biosciences' Series A financing round, is a significant step forward in the clinical development of their innovative Nerve Trace imaging technology. Axogen is globally recognized for its surgical solutions aimed at restoring peripheral nerve function, making their collaboration with Trace both timely and critical as medical advancements continue to evolve in this specialized field.

The Nerve Trace technology utilizes near-infrared fluorescence imaging, which is designed to allow real-time visualization of nerves during surgical procedures. This capability is crucial, particularly in situations where nerves are hidden from view by surrounding tissues. This technology presents two major clinical benefits. Firstly, it enhances surgeons’ ability to identify and avoid nerve damage during complex surgeries. Secondly, in instances of nerve injury, it aids in precisely localizing and assessing the nerve, which bolsters surgical repair efforts.

As part of its ongoing developments, Trace Biosciences has initiated its Phase I clinical trial for its lead product, Nerve Trace Dx, following the FDA's clearance of its Investigational New Drug (IND) application in December 2025. The funds from Axogen's investment will be directed toward facilitating Trace’s subsequent Phase II and III clinical trials, leading to the eventual New Drug Application (NDA).

Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences, expressed enthusiasm about the partnership with Axogen, stating, "We're pleased to welcome Axogen, a company that shares our commitment to protecting nerve function, as a strategic partner in this next phase of our growth. This investment strengthens our ability to advance Nerve Trace through the clinical work ahead, giving surgeons visibility into nerves they've not been able to see before." The partnership is built on a shared vision of improving patient outcomes through enhanced nerve care.

Michael Dale, President and CEO of Axogen, emphasized the importance of visibility in nerve treatment, stating, "You can't treat what you can't see." He further explained that this collaboration is a key component of Axogen's mission to set a new standard in the restoration of peripheral nerve function. By empowering surgeons with the ability to visualize nerves in real-time, whether to protect or treat, the capabilities of this technology align with Axogen’s overarching goals.

About Trace Biosciences

Trace Biosciences is a pioneering clinical-stage biotechnology company focused on developing nerve-targeted imaging solutions for surgeries. Founded by experts in imaging, chemistry, and translational medicine, the company's goal is to make safe and precise surgical practices a reality by ensuring that nerves are visible in every operating room. By creating a new class of small-molecule imaging agents, Trace aims to revolutionize how surgeons approach nerve management during operations.

For further insights and updates, you can visit Trace Biosciences' official website.

About Axogen, Inc.

Axogen, trading under the ticker AXGN, is a leader in the field of peripheral nerve regeneration and repair technologies. Committed to enhancing the quality of life for patients with nerve injuries, Axogen provides a portfolio of innovative, clinically validated repair solutions to improve patient outcomes following nerve trauma or surgical procedures. Their products, such as Avance® and Axoguard series, are integral to restoring crucial nerve function across various clinical environments. For more information about their offerings, visit Axogen's official website.